Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Chondroitin Clear all

Conditions: Vitreous Detachment, Diabetic Retinopathy
Interventions: Vitrase; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Beverly Hills, California • New York, New York • McAllen, Texas + 1 more

Conditions: MPS IV A
Interventions: BMN 110 Weekly, Placebo, BMN 110 Every Other Week; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 5 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 3 more

Conditions: Complications of Corneal Transplant
Interventions: Corneal donor storage in Optisol GS media solution, Life 4°C solution for cornea storage; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 30 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Indianapolis, Indiana • Grand Rapids, Michigan • Cleveland, Ohio + 1 more

Conditions: Mucopolysaccharidosis VI
Interventions: N-acetylgalactosamine 4-sulfatase, Placebo/rhASB; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 7 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Novato, California

Conditions: Scleroderma, Sclerodactyly, Systemic Sclerosis
Interventions: hyaluronidase; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Osteoarthritis
Interventions: glucosamine, chondroitin sulfate, glucosamine and chondroitin sulfate combined, celecoxib; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 40 Years and older
Enrollment: 1,588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 16
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 12 more

Conditions: Drug Hypersensitivity
Interventions: Vitrase; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Davis, California

Conditions: Joint Health
Interventions: MyCondro 300mg, MyCondro 600mg; Dietary Supplement
Lead sponsor: Lesaffre International; Industry
Eligibility: 45 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cataracts
Interventions: DisCoVisc, DuoVisc, BioVisc, Healon5, Amvisc Plus; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 49 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Pain
Interventions: Vitrase (ovine hyaluronidase) Lyophilized; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetic Foot Ulcer (DFU)
Interventions: FoundationDRS Solo, Standard of Care; Other
Lead sponsor: Samaritan Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Mucopolysaccharidosis VI
Interventions: N-acetylgalactosamine 4-sulfatase; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 5 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Novato, California

Conditions: Allergic Skin Reaction
Interventions: Hyaluronidase, Histamine, Saline; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 253 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 5
States / cities: Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more

Conditions: Cardiothoracic Surgery
Interventions: HEMOBLAST Bellows, FLOSEAL; Device
Lead sponsor: Biom'Up France SAS; Industry
Eligibility: Not listed
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Los Angeles, California • Honolulu, Hawaii • New Orleans, Louisiana + 1 more

Conditions: Osteoarthritis
Interventions: Glucosamine, Chondroitin; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 21 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Head and Neck Cancer, Relapse, Recurrent, Refractory Cancer
Interventions: Cyclophosphamide, Fludarabine, Cell Therapy; Drug · Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions: BMN 110; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Up to 5 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Oakland, California • Manhasset, New York

Conditions: Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions: BMN 110; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 5 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Oakland, California • Chicago, Illinois

Conditions: Mucopolysaccharidosis VI
Interventions: N-acetylgalactosamine 4-sulfatase; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Novato, California

Conditions: Thermal Burn
Interventions: thin Integra® (125 cm2); Device
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 125 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Search by objective public record fields.

Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Life 4°C Versus Optisol in Corneal Storage Media

Study of rhASB in Patients With Mucopolysaccharidosis VI

Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma

Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health

DisCoVisc Comparative Evaluation

Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics

Evaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers

Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

Absorption and Distribution of Glucosamine and Chondroitin

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

Single-Stage Integra Reconstruction in Burns